Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
- 28 March 2001
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 37 (5) , 1323-1328
- https://doi.org/10.1016/s0735-1097(01)01165-2
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseJournal of the American College of Cardiology, 2000
- Platelet Glycoprotein IIb/IIIa InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarctionJournal of the American College of Cardiology, 1999
- Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary interventionThe American Journal of Cardiology, 1999
- Evaluation of Platelet Membrane Glycoproteins in Coronary Artery DiseaseCirculation, 1999
- Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and α v β 3 IntegrinsCirculation, 1998
- Effect of Glycoprotein IIb-IIIa Receptor Antagonism on Platelet Membrane Glycoproteins after Coronary Stent PlacementThrombosis and Haemostasis, 1998
- 7E3 Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Cross-reacts With the Leukocyte Integrin Mac-1 and Blocks Adhesion to Fibrinogen and ICAM-1Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Abciximab (c7E3 Fab)Drugs, 1994
- A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.Journal of Clinical Investigation, 1983